Health Economics›Acute promyelocytic leukemia›Consolidation after upfront therapy

Consolidation after upfront therapy

Acute promyelocytic leukemia · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Arsenic trioxide and ATRA Variant #03	—	R 231 223	56d	—	—	—	—	1
Arsenic trioxide-ATRA and Daunorubicin Variant #01	—	R 110 531	49d	—	—	—	—	—
ATRA and Daunorubicin Variant #01	—	R 55 345	90d	—	—	—	—	—
Cytarabine and Idarubicin, then Etoposide and Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA Variant #01	—	R 51 840	—	—	—	—	—	—
Cytarabine and Idarubicin, then Etoposide and Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine N/A - protocol	—	R 46 799	—	—	—	—	—	—
Cytarabine and Idarubicin, then Mitoxantrone, then Cytarabine and Idarubicin, with ATRA Variant #01	—	R 43 822	30d	—	—	—	—	—
Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA Variant #01	—	R 39 574	30d	—	—	—	—	—
Idarubicin, then Mitoxantrone, then Idarubicin Variant #01	—	R 32 222	30d	—	—	—	—	—
Cytarabine and Daunorubicin Variant #03	—	R 26 542	—	—	—	—	—	—
Daunorubicin monotherapy Variant #01	—	R 19 658	—	—	—	—	—	—
Cytarabine and Idarubicin Variant #01	—	R 4 599	30d	—	—	—	—	—
Arsenic trioxide monotherapy N/A - intrathecal component	—	R 0	—	—	—	—	—	—

12 of 12 regimens shown